论文部分内容阅读
目的探讨恩替卡韦对乙型肝炎肝硬化合并肝源性糖尿病的治疗作用。方法选择2010年10月-2013年6月收治的86例乙型肝炎肝硬化合并肝源性糖尿病患者,随机分为观察组和对照组,每组各43例,对照组进行护肝治疗同时注射诺和灵30 R,观察组在护肝治疗基础上口服恩替卡韦,观察两组患者血糖以及肝功能的控制情况。结果观察组患者病毒学应答率和糖尿病控制率分别为74.4%(32/43)和79.1%(34/43),均高于对照组58.1%(25/43)和44.2%(19/43),差异具有统计学意义(P<0.05);治疗后,两组患者肝功能均改善,观察组患者肝功能改善程度明显优于对照组,ALT、AST、TBil明显降低,与对照组比较,差异具有显著性(P<0.05);ALB表现为升高,与对照组比较,结果具有统计学意义(P<0.05)。结论恩替卡韦可有效抑制乙肝病毒,对肝功能恢复有一定促进作用,同时能够控制血糖,对肝源性糖尿病有一定治疗作用。
Objective To investigate the therapeutic effect of entecavir on hepatitis B cirrhosis with liver-derived diabetes. Methods From October 2010 to June 2013, 86 patients with hepatitis B cirrhosis and liver-derived diabetes mellitus were randomly divided into observation group and control group, with 43 cases in each group. The control group was treated with hepatoprotective therapy Novo Ling 30R, the observation group in the treatment of liver based on oral administration of entecavir observed two groups of patients with blood glucose and liver function control. Results The virological response rate and diabetes control rate in the observation group were 74.4% (32/43) and 79.1% (34/43), respectively, which were significantly higher than those in the control group (58.1% vs 44.2%, 19/43) , The difference was statistically significant (P <0.05); after treatment, both groups of patients with liver function improved, the observed group of patients with liver function improved significantly better than the control group, ALT, AST, TBil significantly reduced compared with the control group, the difference (P <0.05). ALB showed an increase, compared with the control group, the results were statistically significant (P <0.05). Conclusion Entecavir can effectively inhibit the hepatitis B virus, which can promote the recovery of liver function and control the blood sugar at the same time. It has a certain therapeutic effect on liver-derived diabetes mellitus.